Vaccines offer the proven ability to protect against both known and emerging infectious pathogens and are being leveraged in novel applications including for the treatment of cancer.
A variety of vaccine manufacturing strategies exist, ranging from conventional egg-based processes to mRNA and virus like particle (VLP)-based approaches. Each vaccine modality offers a different combination of advantages and disadvantages, and presents different production challenges. Use of templated processes for vaccine manufacturing can help accelerate time to market, maximize productivity, and contribute to greater cost efficiencies. The following pages describe templated production workflows in a step-by-step manner for several vaccine modalities including: · Cell-based attenuated viral vaccines · Egg- and cell-based influenza vaccines · Adenovirus-based vaccines · VLP-based vaccines Detailed case studies are provided to guide vaccine developers and manufacturers through each unit operation of the respective processes from upstream production to downstream purification, formulation and final fill and finish. Key considerations are highlighted for each step to help ensure vaccine workflows and productivity are optimized. Links to an extensive set of resources and product information are also included. Read more online here: Streamline and accelerate manufacturing processes for attenuated viral vaccines Explore strategies to enhance egg- and cell-based influenza vaccine manufacturing Optimize your adenovirus-based viral vaccine manufacturing process Improve the productivity of virus-like particle (VLP) vaccine manufacturing processes |